Navigation Links
Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
Date:9/14/2012

REDMOND, Wash., Sept 14, 2012 /PRNewswire/ -- Onconome, Inc. today reported the results of studies on 431 patients based upon the blood test it has developed to determine an individual's probability of having colorectal cancer (CRC). The results of the studies have been published in the September issue of the "American Journal of Cancer Research" and demonstrate that Onconome's test is highly sensitive (93.75%) and specific (82.89%) to CRC and has a Negative Predictive Value of 99.9775% (NPV), meaning that a negative test result indicates an extremely low probability of a given patient having CRC. Onconome also reported that two additional clinical trials are now underway at three independent sites to further validate the test's efficacy as a CRC pre-screening tool.

The first of these trials (ONC04) is designed to evaluate blood samples from subjects who are 50 to 80 years old and therefore considered to be at elevated risk of CRC and who are scheduled for colonoscopy. Their samples will then be compared to their colonoscopy results to validate the test's sensitivity, specificity and NPV. The second trial (ONC05) includes patients who have already been diagnosed with CRC or pre-cancerous adenomas via colonoscopy or sigmoidoscopy and are scheduled for surgery. The endpoint of this trial is to establish the test's efficacy in detecting dangerous pre-cancerous conditions in the colon. Both trials are expected to be completed in 2013.

"It's an established fact that nearly half of adults age 50 or older have not had a colonoscopy in the past ten years and that relatively few use fecal occult blood test home kits," said Ray Cairncross, chief executive officer of Onconome. "A simple blood test which addresses these low compliance rates and provides both patients and their clinicians with an accurate assessment of an individual's risk of CRC would be an important tool in deciding whether to have a colonoscopy or sigmoidoscopy."

Onconome is a privately held clinical-stage company committed to the discovery and development of products focused on the early detection of colorectal cancer. See www.onconome.com.


'/>"/>
SOURCE Onconome, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Management Change
2. Neuralstem Announces Proposed Public Offering
3. PPCE Announces Strategic Partnership With ECLINSO AG
4. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Henry Schein Announces New $500 Million Credit Facility
8. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
9. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
10. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
11. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
(Date:5/23/2016)... ... 2016 , ... During Logan University’s (Logan) Spring ... awarded $6,000 in chiropractic scholarships. The winners of the three $2,000 scholarships ... fifth trimester of classes at Logan. , “Standard Process has been extremely generous ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hospice of Westchester (HOW), ... for over 24 years, recently hosted its sixth annual Celebration of Life Memorial ... remembrance ceremonies, each concluding with the release of Monarch butterflies that honored the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... ... May 23, 2016 , ... While new ... epidemic (1), physicians are not legally required to follow them. In the absence ... 3, 4). Novus Medical Detox Center , a leading Florida-based drug treatment ...
Breaking Medicine News(10 mins):